S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:MEIP

MEI Pharma (MEIP) Stock Price, News & Analysis

$4.24
-0.01 (-0.24%)
(As of 04:00 PM ET)
Today's Range
$4.21
$4.28
50-Day Range
$4.15
$6.24
52-Week Range
$4.13
$7.97
Volume
13,916 shs
Average Volume
21,986 shs
Market Capitalization
$28.24 million
P/E Ratio
1.43
Dividend Yield
N/A
Price Target
$7.00

MEI Pharma MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
66.3% Upside
$7.00 Price Target
Short Interest
Healthy
0.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.69mentions of MEI Pharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $3.24 to ($4.98) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.47 out of 5 stars

Medical Sector

85th out of 948 stocks

Pharmaceutical Preparations Industry

30th out of 440 stocks


MEIP stock logo

About MEI Pharma Stock (NASDAQ:MEIP)

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEIP Stock Price History

MEIP Stock News Headlines

MEI Pharma Inc (MEIP)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
MEIP MEI Pharma, Inc.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
MEI Pharma Inc.
Is MEI Pharma (MEIP) Attractively Priced?
Acceleron Pharma
Stifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)
MEI Pharma Inc MEIP
MEI Pharma Recommends Stockholders Not to Consent
See More Headlines
Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Ex-Dividend for 12/6 Dividend
11/16/2023
Dividend Payable
12/06/2023
Today
3/04/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MEIP
Previous Symbol
NASDAQ:MSHL
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+66.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-31,840,000.00
Pretax Margin
27.32%

Debt

Sales & Book Value

Annual Sales
$48.82 million
Book Value
$3.70 per share

Miscellaneous

Free Float
6,403,000
Market Cap
$28.04 million
Optionable
Optionable
Beta
0.78
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. David M. Urso B.A. (Age 60)
    Esq., J.D., CEO, President & Director
    Comp: $748.46k
  • Dr. Richard G. Ghalie M.D. (Age 66)
    MBA, Chief Medical Officer
    Comp: $627.76k
  • Mr. Justin J. File (Age 54)
    CFO & Corporate Secretary
  • Ms. Yomara Gomez-Naiden
    Senior Vice President of Operations & Quality
  • Ms. Nicole Chyoko Iida
    Vice President of Legal Affairs
  • Ms. Anne Frese
    Chief People Officer
  • Dr. Robert D. Mass (Age 70)
    Strategic Advisor
    Comp: $201.68k
  • Mr. David A. Walsey J.D.
    L.L.M., Senior Vice President of Corporate Affairs














MEIP Stock Analysis - Frequently Asked Questions

Should I buy or sell MEI Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares.
View MEIP analyst ratings
or view top-rated stocks.

What is MEI Pharma's stock price target for 2024?

1 brokerages have issued 1 year target prices for MEI Pharma's stock. Their MEIP share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price.
View analysts price targets for MEIP
or view top-rated stocks among Wall Street analysts.

How have MEIP shares performed in 2024?

MEI Pharma's stock was trading at $5.80 at the beginning of the year. Since then, MEIP shares have decreased by 27.4% and is now trading at $4.21.
View the best growth stocks for 2024 here
.

Are investors shorting MEI Pharma?

MEI Pharma saw a decline in short interest in February. As of February 15th, there was short interest totaling 10,100 shares, a decline of 97.0% from the January 31st total of 331,500 shares. Based on an average trading volume of 33,900 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company's stock are short sold.
View MEI Pharma's Short Interest
.

When is MEI Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MEIP earnings forecast
.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($2.60) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($2.60). The company had revenue of $13.39 million for the quarter, compared to analyst estimates of $9.98 million. MEI Pharma had a net margin of 39.06% and a trailing twelve-month return on equity of 39.72%.

How often does MEI Pharma pay dividends? What is the dividend yield for MEI Pharma?

MEI Pharma declared a dividend on Monday, November 6th. Stockholders of record on Friday, November 17th will be paid a dividend of $1.75 per share on Wednesday, December 6th. The ex-dividend date of this dividend is Thursday, November 16th.
Read our dividend analysis for MEIP
.

When did MEI Pharma's stock split?

MEI Pharma shares reverse split on the morning of Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of MEI Pharma own?
Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Cable Car Capital LLC (9.18%), Vanguard Group Inc. (5.85%), Bridgeway Capital Management LLC (0.40%), Northern Trust Corp (0.37%), National Bank of Canada FI (0.09%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Anson Funds Management Lp and Charles V Baltic III.
View institutional ownership trends
.

How do I buy shares of MEI Pharma?

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MEIP) was last updated on 3/4/2024 by MarketBeat.com Staff